My last bit of DD for those that wish to use it. --
In mCRPC patients, a CTC value of 5. This was confirmed with studies from 2008 with Hazard ratio and p 5. This is only for the mCRPC patients, not non-metastatic. There is a reason for huge institutional buildup. Half these people will be living longer than the controls by a long shot. That is my guess based on studies that have been confirmed.
A lot of inaccurate information is being tossed at individuals. I recommend reading for oneself. If you notice what happened with MDVN, they had success with chemotherapy-naive low symptom metastatic patients. In the case of PGNX, they are trying to treat patients who have failed 1st/2nd/3rd line therapies and are likely to die in 6-12 months. This is a last resort. This is a last ditch effort. Don't let someone fool you about neutopenia. Look at the early trials of the early taxanes and how many patients died.
What the abstract has shown is very similar results (so far only based on markers as addl data has not been released) to what Xtandi has done in chemo-naive patients but they have done so in those that have failed prior chemo and continues to progress. They are treating completely different populations.
We can rant on and on about what is correct but unless you truly understand the small details, it is hard to understand the real significance of any data, especially when incomplete.
Maybe I am fighting a lost battle but I hope otherwise.
Phase II conclusions in the abstract show the Efficacy endpoints as below.
- Changes in tumor assessments (RECIST 1.1 criteria) greater or equal to 30%
- Changes in serum PSA and circulating tumor cells (lower CTC # and PSA)